{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T21:44:06Z","timestamp":1790459046611,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.tips.2008.12.002","type":"journal-article","created":{"date-parts":[[2009,2,8]],"date-time":"2009-02-08T04:20:00Z","timestamp":1234066800000},"page":"148-155","source":"Crossref","is-referenced-by-count":252,"title":["Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders"],"prefix":"10.1016","volume":"30","author":[{"given":"P. Jeffrey","family":"Conn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig W.","family":"Lindsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2008.12.002_bib1","series-title":"The Synaptic Organization of the Brain","first-page":"346","article-title":"Hippocampus","author":"Brown","year":"1990"},{"key":"10.1016\/j.tips.2008.12.002_bib2","series-title":"The Biochemical Basis of Neuropharmacology","author":"Cooper","year":"1996"},{"key":"10.1016\/j.tips.2008.12.002_bib3","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.conb.2006.09.002","article-title":"The role of acetylcholine in learning and memory","volume":"16","author":"Hasselmo","year":"2006","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tips.2008.12.002_bib4","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","article-title":"Re-emergence of striatal cholinergic interneurons in movement disorders","volume":"30","author":"Pisani","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2008.12.002_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000113712","article-title":"M1 muscarinic agonists target major hallmarks of Alzheimer's disease \u2013 the pivotal role of brain M1 receptors","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.tips.2008.12.002_bib6","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tips.2008.12.002_bib7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1046\/j.1460-9568.2003.02588.x","article-title":"Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity","volume":"17","author":"Bymaster","year":"2003","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.tips.2008.12.002_bib8","unstructured":"Katzenschlager, R. et al. (2003) Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst. Rev., CD003735"},{"key":"10.1016\/j.tips.2008.12.002_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrd2379","article-title":"Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development","volume":"6","author":"Wess","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2008.12.002_bib10","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12035-008-8031-2","article-title":"Therapeutic strategies for Alzheimer's disease","volume":"37","author":"Barten","year":"2008","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.tips.2008.12.002_bib11","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1021\/jm990607u","article-title":"Therapeutic opportunities for muscarinic receptors in the central nervous system","volume":"43","author":"Felder","year":"2000","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2008.12.002_bib12","doi-asserted-by":"crossref","first-page":"10422","DOI":"10.1523\/JNEUROSCI.1850-08.2008","article-title":"Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor reduces amyloid processing and produces antipsychotic-like activity in rats","volume":"28","author":"Jones","year":"2008","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2008.12.002_bib13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2760","article-title":"Allosteric modulators of GPCRs as a novel approach for treatment of CNS disorders","volume":"8","author":"Conn","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2008.12.002_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors","volume":"47","author":"May","year":"2007","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.tips.2008.12.002_bib15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1124\/mol.52.1.172","article-title":"Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors","volume":"52","author":"Jakubik","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib16","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1124\/jpet.103.060590","article-title":"Investigation of the interaction of a putative allosteric modulator, N-(2,3-diphenyl-1,2,4-thiadiazole-5-(2H)-ylidene) methanamine hydrobromide (SCH-202676), with M1 muscarinic acetylcholine receptors","volume":"308","author":"Lanzafame","year":"2004","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2008.12.002_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1124\/mol.65.1.257","article-title":"Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity","volume":"65","author":"Lazareno","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib18","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1124\/mol.53.3.573","article-title":"Subtype-selective positive cooperative interactions between brucine analogues and acetylcholine at muscarinic receptors: radioligand binding studies","volume":"53","author":"Lazareno","year":"1998","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1124\/mol.59.1.30","article-title":"SCH-202676: an allosteric modulator of both agonist and antagonist binding to G protein-coupled receptors","volume":"59","author":"Fawzi","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib20","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1124\/mol.61.6.1297","article-title":"Discovery of an ectopic activation site on the M1 muscarinic receptor","volume":"61","author":"Spalding","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib21","doi-asserted-by":"crossref","first-page":"13674","DOI":"10.1073\/pnas.1835612100","article-title":"N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-d-aspartate receptor activity","volume":"100","author":"Sur","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2008.12.002_bib22","first-page":"S117","article-title":"TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antypsychotic-like effects in vivo","volume":"31","author":"Jones","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2008.12.002_bib23","first-page":"S26","article-title":"Muscarinic receptor activiation for the treatment of schizophrenia","volume":"31","author":"Kinney","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.tips.2008.12.002_bib24","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjp.2008.152","article-title":"Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1","volume":"154","author":"Langmead","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1124\/jpet.108.141788","article-title":"G protein coupling and signaling pathway activation by M1 muscarinic acetylcholine receptor orthosteric and allosteric agonists","volume":"327","author":"Thomas","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2008.12.002_bib26","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","article-title":"M1 receptors play a central role in modulating AD-like pathology in transgenic mice","volume":"49","author":"Caccamo","year":"2006","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2008.12.002_bib27","unstructured":"Lebon, G. et al. (2008) Mutagenic mapping suggests a novel binding mode for selective agonists of M1 muscarinic acetylcholine receptors. Mol. Pharmacol. http:\/\/molpharm.aspetjournals.org 10.1124\/mol.108.050963"},{"key":"10.1016\/j.tips.2008.12.002_bib28","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1124\/mol.107.040097","article-title":"N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hydroxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors","volume":"73","author":"Chen","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib29","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1016\/j.bmcl.2008.09.023","article-title":"Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I. Exploration of alternative benzyl and privileged structure moieties","volume":"18","author":"Bridges","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2008.12.002_bib30","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.1016\/j.bmcl.2008.09.032","article-title":"Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part II. Amides, sulfonamides and ureas: the effect of capping the distal basic piperidine nitrogen","volume":"18","author":"Miller","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2008.12.002_bib31","unstructured":"Marlo, J. et al. Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol. Pharmacol. http:\/\/molpharm.aspetjournals.org 10.1124\/mol.108.052886"},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2008.12.002_bib32","doi-asserted-by":"crossref","first-page":"T761","DOI":"10.1016\/j.jalz.2008.05.2375","article-title":"Allosteric potentiation of the M1 muscarinic receptor provides unprecedented selectivity and a novel therapeutic strategy for the treamtent of alzheimer's disease","volume":"4","author":"Ray","year":"2008","journal-title":"Alzheimers Dement."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2008.12.002_bib33","doi-asserted-by":"crossref","first-page":"T770","DOI":"10.1016\/j.jalz.2008.05.2402","article-title":"In vivo pharmacodynamic effects of BQCA, a novel selective allosteric M1 receptor modulator","volume":"4","author":"Wittmann","year":"2008","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.tips.2008.12.002_bib34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch. Neurol."},{"issue":"Suppl. 4","key":"10.1016\/j.tips.2008.12.002_bib35","first-page":"S16","article-title":"The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease","volume":"11","author":"Bodick","year":"1997","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.tips.2008.12.002_bib36","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00019052-200208000-00007","article-title":"Neuropsychiatric symptoms in the dementias","volume":"15","author":"Assal","year":"2002","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.tips.2008.12.002_bib37","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1185\/030079902125000813","article-title":"Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series","volume":"18","author":"Bullock","year":"2002","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2008.12.002_bib38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1017\/S1041610203008639","article-title":"Treating Alzheimer's disease with cholinesterase inhibitors: what have we learned so far?","volume":"14","author":"Feldman","year":"2002","journal-title":"Int. Psychogeriatr."},{"issue":"Suppl. 1","key":"10.1016\/j.tips.2008.12.002_bib39","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S1041610203008652","article-title":"The ABC of Alzheimer's disease: behavioral symptoms and their treatment","volume":"14","author":"Grossberg","year":"2002","journal-title":"Int. Psychogeriatr."},{"issue":"Suppl. 2","key":"10.1016\/j.tips.2008.12.002_bib40","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000051193","article-title":"Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease","volume":"9","author":"Kaufer","year":"1998","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"10.1016\/j.tips.2008.12.002_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.tips.2008.12.002_bib42","first-page":"20","article-title":"The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia","author":"Rosler","year":"2002","journal-title":"Int. J. Clin. Pract. Suppl."},{"key":"10.1016\/j.tips.2008.12.002_bib43","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.tips.2008.12.002_bib44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.tips.2008.12.002_bib45","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/S0024-3205(01)01059-1","article-title":"Elucidating the role of muscarinic receptors in psychosis","volume":"68","author":"Felder","year":"2001","journal-title":"Life Sci."},{"key":"10.1016\/j.tips.2008.12.002_bib46","doi-asserted-by":"crossref","first-page":"15312","DOI":"10.1073\/pnas.261583798","article-title":"Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice","volume":"98","author":"Gerber","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2008.12.002_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1568007023339544","article-title":"Direct and indirect modulation of the N-methyl d-aspartate receptor","volume":"1","author":"Marino","year":"2002","journal-title":"Curr. Drug Target. CNS Neurol. Disord."},{"key":"10.1016\/j.tips.2008.12.002_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2174\/1568026024607553","article-title":"Cholinergic agonists and the treatment of Alzheimer's disease","volume":"2","author":"Messer","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.tips.2008.12.002_bib49","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1523\/JNEUROSCI.21-14-05239.2001","article-title":"Hyperactivity and intact hippocampus-dependent learning in mice lacking the M1 muscarinic acetylcholine receptor","volume":"21","author":"Miyakawa","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2008.12.002_bib50","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nchembio.2007.55","article-title":"An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission","volume":"4","author":"Shirey","year":"2008","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.tips.2008.12.002_bib51","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1124\/jpet.108.140350","article-title":"Centrally active allosteric potentiators of the M4 muscarinic acetylcholine receptor reverse amphetamine-induced hyperlocomotion behavior in rats","volume":"327","author":"Brady","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.tips.2008.12.002_bib52","doi-asserted-by":"crossref","first-page":"10978","DOI":"10.1073\/pnas.0800567105","article-title":"Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia","volume":"105","author":"Chan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2008.12.002_bib53","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1124\/mol.64.3.731","article-title":"A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5)","volume":"64","author":"O\u2019Brien","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.tips.2008.12.002_bib54","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1016\/j.bmcl.2008.05.091","article-title":"Synthesis and SAR of a mGluR5 allosteric partial antagonist lead: Unexpected modulation of pharmacology with slight structural modifications to a 5-(phenylethynyl)pyrimidine scaffold","volume":"18","author":"Sharma","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614709000133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614709000133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,11]],"date-time":"2020-03-11T09:49:14Z","timestamp":1583920154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614709000133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0165614709000133"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2008.12.002","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}